Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise.
The aim of this study was to characterise the effect of prolonged low doses of recombinant erythropoietin (r-HuEPO) on the responses to submaximal and maximal exercise. Volunteer recreational athletes ( n=21) were divided into three groups: r-HuEPO+intravenous iron (EPO+IV, n=7), r-HuEPO+oral iron (EPO+OR, n=9) and placebo ( n=5). During the 12 week study, r-HuEPO or saline injections were given three times a week for the first 8 weeks and for the final 4 weeks the subjects were monitored but no injections were administered. The r-HuEPO doses were 50 IU x kg(-1) body mass for 3 weeks and 20 IU x kg(-1) body mass for the next 5 weeks. An exercise test comprising three submaximal intensities and then increments to elicit maximal aerobic power (VO2max ) was conducted during weeks 0, 4, 8 and 12. During week 0, the mean intensity of the submaximal stages was 60%, 72% and 81%. Blood taken at rest was analysed twice a week for haematocrit (Hct). The relative increases in at weeks 4, 8 and 12 were 7.7%, 9.7% and 4.5%, respectively, for the EPO+IV group; 6.0%, 4.7% and 3.1% for the EPO+OR group; and -0.5%, -0.1% and -1.0% for the placebo group, where the improvements at week 12 for the EPO+IV and EPO+OR groups remained significantly above week 0 values. The Hct was significantly elevated by 0.06 and 0.07 units at week 3 in the EPO+IV and EPO+OR groups, respectively, and was stable during the 5 weeks of low-dose r-HuEPO. After 8 weeks of r-HuEPO use, plasma lactate concentration tended to be lower at exercise intensities ranging from 60% to 100%. This study confirmed the ability of low doses of r-HuEPO to maintain Hct and at elevated levels.
Russell
Gabrielle
G
Department of Physiology, Australian Institute of Sport, Canberra, Australia.
Gore
Christopher J
CJ
Ashenden
Michael J
MJ
Parisotto
Robin
R
Hahn
Allan G
AG
D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D002245:Carbon Dioxide / Q000032:analysis; D004334:Drug Administration Schedule; D004906:Erythrocyte Count; D004921:Erythropoietin / Q000008:administration & dosage*; D015444:Exercise / Q000502:physiology*; D005080:Exercise Test / Q000187:drug effects* / Q000379:methods; D005260:Female; D006339:Heart Rate / Q000502:physiology; D006400:Hematocrit; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007275:Injections, Intravenous; D007501:Iron / Q000008:administration & dosage*; D019344:Lactic Acid / Q000097:blood; D008297:Male; D010101:Oxygen Consumption; D010919:Placebos; D011994:Recombinant Proteins; D012156:Reticulocytes; D016896:Treatment Outcome
D010919:Placebos; D011994:Recombinant Proteins; D004921:Erythropoietin; D002245:Carbon Dioxide; D019344:Lactic Acid; D007501:Iron